Advertisement

Intrakavitäre Chemotherapie

  • U. Fink
  • E. D. Kreuser
  • E. Seifried
  • W. Schreml
  • J. Preiss

Zusammenfassung

Die Metastasierung in das ZNS ist eine häufige und gefürchtete Komplikation maligner Tumoren. Klinische Symptome, insbesondere neurologische Störungen und Funktionsausfälle, die durch ZNS-Metastasen verursacht werden, treten bei 10–20% aller Patienten auf. Autoptisch ist der Anteil an ZNS-Metastasen jedoch noch wesentlich höher.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Aur RJA et al (1972) A comparative study of central nervous system irradiation and intensive chemotherapy early in remission of childhood lymphocytic leukemia, Cancer 29:381–391PubMedCrossRefGoogle Scholar
  2. 2.
    Aur RJA et al (1973) Comparison of two methods of preventing central nervous system leukemia. Blood 42:349–357PubMedGoogle Scholar
  3. 3.
    Balis FM et al (1985) Remission induction of meningeal leukemia with high-dose intravenous methotrexate. J Clin Oncol 3:485–489PubMedGoogle Scholar
  4. 4.
    Band PR et al (1973) Treatment of central nervous system leukemia with intrathecal cytosine-arabinoside. Cancer 32:744–748PubMedCrossRefGoogle Scholar
  5. 5.
    Blasberg RG (1977) Methotrexate, cytosin-arabinosid, and BCNU concentration in brain after ventriculo-cisternal perfusion. Cancer Treat Rep 61:625–631PubMedGoogle Scholar
  6. 6.
    Bleyer WA et al (1973) Pharmacokinetics and neurotoxicity of intrathecal methotrexate therapy. N Engl J Med 289:770–773PubMedCrossRefGoogle Scholar
  7. 7.
    Bleyer WA et al (1978) „Concentration x time“methotrexate via a subcutaneous reservoir: A less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 51:835–842PubMedGoogle Scholar
  8. 8.
    Bleyer WA, Dedrick RL (1977) Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 61:70–708Google Scholar
  9. 9.
    Bleyer WA (1977) Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-rehted pharmacokinetics. Cancer Treat Rep 61:1419–1425PubMedGoogle Scholar
  10. 10.
    Bleyer WA (1981) Neurologic sequelae of methotrexate and ionizing radiation: A new classification. Cancer Treat Rep 38:65–68Google Scholar
  11. 11.
    Bunn P et al (1976) Central nervous system complications in patients with diffuse and undifferentiated lymphoma: Leukemia revisited. Blood 41:3–10Google Scholar
  12. 12.
    Dangio GJ et al (1981) Evaluation of radiation therapy factors in the prophylactic central nervous system irradiation for children leukemia: A report from the children’s cancer study group. Int J Radiât Oncol Biol Phys 7:1031–1038CrossRefGoogle Scholar
  13. 13.
    DiStefano A et al (1979) The natural history of breast cancer patients with brain metastases. Cancer 44:1913–1918CrossRefGoogle Scholar
  14. 14.
    Engelhardt P et al (1983) Meningosis neoplastica-intrathekale zytostatische Therapie und liquorzytologische Verlaufsbeobachtung. In: Krauseneck P, Mertens HG (Hrsg) Therapie maligner Neoplasien des Gehirns. Perimed, Erlangen, pp 125–129Google Scholar
  15. 15.
    Ettinger LJ et al (1982) Pharmacokinetics of methotrexate following intravenous and intraventicular administration in acute lymphocytic leukemia and non-Hodgkin’s lymphoma. Cancer 50:1676 ffPubMedCrossRefGoogle Scholar
  16. 16.
    Evans AE et al (1979) The incidence of central nervous system leukemia in children. Cancer 26:404–409CrossRefGoogle Scholar
  17. 17.
    Freund M et al (1983) CNS manifestation in Non-Hodgkin’s lymphoma (NHL). Klin Wochenschr 61:903ffPubMedCrossRefGoogle Scholar
  18. 18.
    Friffin J et al (1971) Lymphomatous leptomeningitis. Am J Med 51:200–208CrossRefGoogle Scholar
  19. 19.
    Giannone L et al (1986) Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 4:68–73PubMedGoogle Scholar
  20. 20.
    Grisold W et al (1984) Klinik und zytologische Diagnostik der meningea-len Neoplasien. In: Hey den HW von, Krauseneck P (Hrsg) Hirnmetastasen — Pathophysiologie, Diagnostik und Therapie. Zuckschwerdt, München (Aktuelle Onkologie, Bd 13), pp85–106Google Scholar
  21. 21.
    Guttin PH et al (1976) Intrathecal N,N′,N″-methylene thiophosphora-mide (Thio-Tepa) in the treatment of malignant meningeal disease. Cancer 38:1471–1475CrossRefGoogle Scholar
  22. 22.
    Hayakawa T et al (1970) Intrathecal chemotherapy. Selection of cytostatic agents. Br J Cancer 24:489–497PubMedCrossRefGoogle Scholar
  23. 23.
    Ho DGW, Frei E (1971) III. Clinical pharmacology of 1-β-D-arabino-furanosylcytosine. Clin Pharmacol Ther 12:944–954PubMedGoogle Scholar
  24. 24.
    Jellinger K (1984) Häufigkeit und Charakteristik der zerebralen Karzinommetastasen. In: Heyden HW von, Krauseneck P (Hrsg) Hirnmetastasen — Pathophysiologie, Diagnostik und Therapie. Zuckschwerdt, München Bern Wien (Aktuelle Onkologie, Bd 13), pp 49–79Google Scholar
  25. 25.
    Kölmel HW et al (1984) Methotrexat-Therapie bei Hirnmetastasen und Meningosis neoplastika. In: Heyden HW von, Krauseneck P (Hrsg) Hirnmetastasen — Pathophysiologie, Diagnostik und Therapie. Zuckschwerdt, München (Aktuelle Onkologie, Bd 13), pp 180–186Google Scholar
  26. 26.
    Komp DM et al (1982) CNS prophylaxis in acute lymphoblastic leukemia. Cancer 50:1931 ffCrossRefGoogle Scholar
  27. 27.
    Krauseneck P (1984) Chemotherapie von Hirnmetastasen. In: Heyden HW von, Krauseneck P (Hrsg) Hirnmetastasen — Pathophysiologie, Diagnostik und Therapie. Zuckschwerdt, München (Aktuelle Onkologie, Bd 13), pp 167–179Google Scholar
  28. 28.
    Kremer WB (1975) Drugs five years later — Cytarabine. Ann Intern Med 8:684–788Google Scholar
  29. 29.
    Lanelma J et al (1980) Change in transfer of methotrexate from spinal fluid to plasma during intrathecal therapy in children and adults. Clin Pharmacokinet 5:465–475CrossRefGoogle Scholar
  30. 30.
    McRae MP, King JC (1976) Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures. Am J Hosp Pharm 33:1010–1013PubMedGoogle Scholar
  31. 31.
    Mende S et al (1938) Erfolgreiche Behandlung von Hirnmetastasen bei Mammakarzinom mit nicht-liquorgängigen Zytostatika und Hormonen. Onkologie 6:58–61CrossRefGoogle Scholar
  32. 32.
    Mertens HG, Reuther P (1980) Indikationen intrathekaler Applikation und Pharmakotherapie von Krankheiten des Liquorraumes. In: Dommasch, Mertens (Hrsg) Cerebrospinalflüssigkeit-CSF. Thieme, StuttgartGoogle Scholar
  33. 33.
    Moss HA et al (1981) The effects of prophylactic treatment of the central nervous system on the intellectual functioning of children with acute lymphocytic leukemia. Am J Med 71:47–52PubMedCrossRefGoogle Scholar
  34. 34.
    Nelson RW, Frank JT (1981) Intrathecal methotrexate-induced neurotoxicities. Am J Hosp Pharm 38:65–688PubMedGoogle Scholar
  35. 35.
    Paterson AHG et al (1982) Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer 49:651–654PubMedCrossRefGoogle Scholar
  36. 36.
    Posner JP, Chernik NL (1978) Intracranial metastases from systemic cancer. Adv Neurol 19:579PubMedGoogle Scholar
  37. 37.
    Posner BJ (1983) Treatment of leptomeningeal metastases from solid tumors. In: Krauseneck P, Mertens HG (Hrsg) Therapie maligne Neoplasien des Gehirns. Perimed, Erlangen, pp 122–125Google Scholar
  38. 38.
    Price RA, Jameson PA (1975) The central nervous system in childhood leukemia: II. Subacute leukoencephalopathy. Cancer 35:306–318PubMedCrossRefGoogle Scholar
  39. 39.
    Ratcheson RA, Ommaya AK (1968) Experience with the subcutaneous cerebrospinal-fluid reservoir. N Engl J Med 279:1025–1031PubMedCrossRefGoogle Scholar
  40. 39a.
    Rosner D. Nemoto T (1986) Chemotherapy induced regression of brain metastases from breast cancer: follow up report. Proc AACR 27:177 (Abstr. 703)Google Scholar
  41. 40.
    Sackmann M et al (1983) Comparison of central nervous system prophylaxis with cranial radiation and intrathecal MTX versus MTX alone in acute lymphoblastic leukemia. Blood 62:241 ffGoogle Scholar
  42. 41.
    Sculier JP (1985) Treatment of meningeal carcinomatosis. Cancer Treatm Rev 12:95–104CrossRefGoogle Scholar
  43. 42.
    Shapiro WR et al (1975) Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293:161–166PubMedCrossRefGoogle Scholar
  44. 43.
    Smith AG et al (1972) Meningeal relapse in Ph1-positive acute lymphoblastic and lymphoid blast crisis of chronic granulocytic leukemia. Is CNS-prophylaxis indicated? Br Med J 3:311 ffCrossRefGoogle Scholar
  45. 44.
    Spiegel RJ et al (1984) Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion. N Engl J Med 311:386–388PubMedCrossRefGoogle Scholar
  46. 45.
    Steinherz P et al (1985) Therapy of CNS leukemia with intraventricular chemotherapy and low-dose neuraxis radiotherapy. J Clin Oncol 3:1217–1226PubMedGoogle Scholar
  47. 46.
    de Visser BW, Somers R, Nooyen WH et al. (1983) Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33:1565–72Google Scholar
  48. 47.
    Wasserström WR et al (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49:759–772PubMedCrossRefGoogle Scholar
  49. 48.
    Wolk RW et al (1974) The incidence of central nervous system leukemia in adults with acute leukemia. Cancer 33:863 ffPubMedCrossRefGoogle Scholar
  50. 49.
    Young RC et al (1979) Central nervous system complications of Non-Hodgkin’s lymphoma. The potential role for prophylactic therapy. Am J Med 66:435–443PubMedCrossRefGoogle Scholar
  51. 50.
    Zuckermann KS et al (1976) High dose methotrexate with Citrovorum-factor in the treatment of advanced non-Hodgkin’s-lymphoma including CNS involvement. Blood 48:983ffGoogle Scholar
  52. 1.
    Austin EH, Wayne Flye M (1979) The treatment of recurrent malignant pleural effusion. Ann Thorac Surg 28:190–203PubMedCrossRefGoogle Scholar
  53. 2.
    Bayly TC, Kisner DL, Sybert A, McDonald JS, Tsou E, Schein PS (1978) Tetracycline und quinacrine in the control for malignant pleural effusions. A randomized trial. Cancer 41:1188–1192PubMedCrossRefGoogle Scholar
  54. 3.
    Kreuser ED (1985) Maligne Pleuraergüsse: Pathophysiologie, Diagnostik und Therapie. Dtsch med Wschr 110:1381–1386PubMedCrossRefGoogle Scholar
  55. 4.
    Kreuser ED, Seifried E, Harsch U, Brass B, Schreml W und Heimpel H (1985) Fibrinpleurodese bei malignen Pleuraergüssen. Dtsch med Wschr 110:1365–1368PubMedCrossRefGoogle Scholar
  56. 5.
    Memon A, Zawadzki ZA (1981) Malignant effusions: Diagnostic evaluation and therapeutic strategy. Curr Probl Cancer 518Google Scholar
  57. 6.
    Uhmann JE, Mauch PM (1985) Treatment of Malignant Pleural Effusions. In: De vita et al, Cancer: Principles and practice of Oncology. Lippincott, Philadelphia Toronto, pp 2145–2149Google Scholar
  58. 7.
    Zaloznik A, Oswald SG, Langin M (1983) Intrapleural tetracycline in malignant pleural effusions. A randomized study. Cancer 51:752–755PubMedCrossRefGoogle Scholar
  59. Davis S, Rambotti P, Grignani F (1984) Intrapericardial tetracycline sklerosis in the treatment of malignant pericardial effusions: An analysis of thirty three cases. J Clin Oncol 2:631–636PubMedGoogle Scholar
  60. Flannery EP, Gregoratos G, Corder MP (1975) Pericardial effusions in patients with malignant diseases. Arch Intern Med 135:976 ffPubMedCrossRefGoogle Scholar
  61. Hill GH, Cohen BI (1970) Pleural pericardial window for palliation of cardiac tamponade due to cancer. Cancer 26:81 ffPubMedCrossRefGoogle Scholar
  62. Martini N, Freimann AH, Watson RC, Hilaris BS (1977) Intrapericardial instillation of radioactive chromic phosphat in malignant pericardial effusion. AJR 128:639 ffPubMedGoogle Scholar
  63. Mauch PM, Ultmann JE (1985) Treatment of malignant pericardial effusion. In: DeVita VT Jr, Hellmann S, Rosenberg SA (eds) Cancer: Principles and practice of oncology (2nd ed), Lippincott, Philadelphia, pp 2141–2144Google Scholar
  64. Smith FE, Lane M, Hudgins PT (1974) Conservative management of malignant pericardial effusion. Cancer 33:47ffPubMedCrossRefGoogle Scholar
  65. Suhrland LG, Weisberger AS (1965) Intracavitary 5-fluorouracil in malignant effusion. Arch Intern Med 116:431–437PubMedCrossRefGoogle Scholar
  66. Appelqvist P, Silvio J, Salmela L, Kostiainen S (1982) On the treatment and prognosis of malignant ascites: Is survival time determined when the abdominal paracentesis is needed? J Surg Oncol 20:238–242PubMedCrossRefGoogle Scholar
  67. Casper ES, Kelsen DP, Alcock NW, Lewis JL Jr: (1983) Ip cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep 67:235–238PubMedGoogle Scholar
  68. Cheung DK, Raaf JH (1982) Selection of patients with malignant ascites for a peritoneovenous shunt. Cancer 50:1204–1209PubMedCrossRefGoogle Scholar
  69. Howell SB, Pfeifle CE, Markman M (1984) Phase I trials and pharmacokinetic studies of intraperitoneal cisplatin, melphalan, methotrexate, and cyta-rabin. In: Howell SB (ed) Intra-arterial and intracavitary cancer chemotherapy. Martinus Nijhoff Publishers, Boston Dordrecht Lancaster, pp. 153–165CrossRefGoogle Scholar
  70. Kaplan RA, Markman M, Lucas WE, Pfeifle C, Howell SB (1985) Infectious peritonitis in patients receiving intraperitoneal chemotherapy. Am J Med 78:49–53PubMedCrossRefGoogle Scholar
  71. Lacy JH, Wieman TJ, Shively EH (1984) Management of malignant ascites. Surg Gynecol Obstet 159:397–412PubMedGoogle Scholar
  72. Markman M, Howell SB, Lucas WE, Pfeifle CE, Green MR (1984) Combined intraperitoneal chemotherapy with cisplatin, cytarabin, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol 2:1321–1326PubMedGoogle Scholar
  73. Mauch PM, Ultmann JE (1985) Treatment of malignant ascites. In: DeVita VT Jr, Hellmann S, Rosenberg SA (eds) Cancer: Principles and practice of oncology (2nd ed.). Lippincott, Philadelphia, pp 2150–2153Google Scholar
  74. Ostrowski MJ, Halstall GM (1982) Intracavitary bleomycin in the management of malignant effusions: a multicenter study. Cancer Treat Rep 66:1903–1907PubMedGoogle Scholar
  75. Ozols RF, Young RC, Myers Ce (1984) Intraperitoneal adriamycin and 5fluorouracil in ovarian cancer. In: Howell SB (ed) Intra-arterial and intracavitary cancer chemotherapy. Martinus Nijhoff Publishers, Boston Dordrecht Lancaster, pp. 187–197CrossRefGoogle Scholar
  76. Ozols RF, Speyer JI, Jenkins J, Myers CE (1984) Phase II trial of 5-FU administered Ip to patients with refractory ovarian cancer. Cancer Treat Rep 68:1229–1232PubMedGoogle Scholar
  77. Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW, Myers CE (1981) Portal levels and hepatic clearance of 5-FU after intraperitoneal administration in humans. Cancer Res 41:1916–1922PubMedGoogle Scholar
  78. Yamada S, Takeda T, Matsumoto K (1983) Prognostic analysis of malignant pleural and peritoneal effusions. Cancer 51:136–140PubMedCrossRefGoogle Scholar
  79. Blumenreich MS, Needles B, Yagoda A, Sogani P, Grabstald H, Whitmore JR (1982) Intravesical cisplatin for superficial bladder tumors. Cancer 50:863–865PubMedCrossRefGoogle Scholar
  80. Brock N, Pohl J (1983) The development of mesna for regional detoxification. Cancer Treat Rev [Suppl A] 10:33–44CrossRefGoogle Scholar
  81. Burkert H (1983) Clincal overview of mesna. Cancer Treat Rev [Suppl A] 10:175–192CrossRefGoogle Scholar
  82. Horn Y, Eidelmann A, Walach N, Ilian M (1981) Intravesical chemotherapy in a controlled trial with thiotepa versus doxorubicin hydrochloride. J Urol 125:652–658PubMedGoogle Scholar
  83. Huland H, Otto U, Klosterhalfen H (1984) Langzeit-Mitomycin-Blaseninstil-lation zur Rezidivprophylaxe und Beeinflussung der Überlebensrate von Patienten mit oberflächlichen Blasenkarzinomen nach transurethraler Resektion. In: Huland H, Klosterhalfen H (Hrsg) Therapie und Rezidivprophylaxe oberflächlicher Harnblasenkarzinome. Thieme, Stuttgart New York, pp 85–93Google Scholar
  84. Rübben H, Dahm HH, Lutzeyer W (1981) Rezidivhäufigkeit und Tumorprogression superfizialer Harnblasenkarzinome. Urologe [A] 20:211–214Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • U. Fink
  • E. D. Kreuser
  • E. Seifried
  • W. Schreml
  • J. Preiss

There are no affiliations available

Personalised recommendations